DrugPatentWatch Database Preview
Email this page to a colleagueSee Plans and Pricing
« Back to Dashboard
Cabotegravir is an investigational drug.
There have been 17 clinical trials for Cabotegravir. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2016.
The most common disease conditions in clinical trials are HIV Infections, Acquired Immunodeficiency Syndrome, and Immunologic Deficiency Syndromes. The leading clinical trial sponsors are ViiV Healthcare, National Institute of Allergy and Infectious Diseases (NIAID), and GlaxoSmithKline.
There are twenty-nine US patents protecting this investigational drug and two hundred and twenty-five international patents.
Recent Clinical Trials for Cabotegravir
|Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)||ViiV Healthcare||Phase 3|
|Long-Acting Cabotegravir Plus VRC01LS for Viral Suppression in HIV-1-Infected Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Phase 2|
|More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents||National Institute of Allergy and Infectious Diseases (NIAID)||Phase 1/Phase 2|
Top disease conditions for Cabotegravir
Top clinical trial sponsors for Cabotegravir
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Cabotegravir||Start Trial||Substituted pyridinones as intermediates in the preparation of polycyclic carbamoylpyridone derivatives||ViiV Healthcare Company (Wilmington, DE)||Start Trial|
|Cabotegravir||Start Trial||Process for preparing substituted pyridinones as intermediates in the preparation of polycyclic carbamoylpyridone derivatives||ViiV Healthcare Company (Wilmington, DE)||Start Trial|
|Cabotegravir||Start Trial||Processes for preparing dolutegravir and cabotegravir and analogues thereof||Lek Pharmaceuticals d.d. (Ljubljana, SI)||Start Trial|
|Cabotegravir||Start Trial||Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness||Shionogi & Co., Ltd. (Osaka, JP) GlaxoSmithKline LLC (Philadelphia, PA)||Start Trial|
|Cabotegravir||Start Trial||(3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5- ,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent||Shionogi & Co., Ltd. (Osaka, JP) VIIV Healthcare Company (Research Triangle Park, NC)||Start Trial|
|Cabotegravir||Start Trial||Processes and intermediates for carbamoylpyridone HIV integrase inhibitors||Shionogi & Co., Ltd. (Osaka, JP) VIIV Healthcare Company (Research Triangle Park, NC)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Cabotegravir||European Patent Office||2549870||2030-03-23||Start Trial|
|Cabotegravir||European Patent Office||3260457||2030-03-23||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|